Febit Establishes US Company
News Aug 15, 2006
febit biotech gmbh has announced the establishment of febit Incorporation, a Delaware Company based in Medford, Boston/USA.
febit Inc. will be supporting all operations throughout America: in the US, Canada and the Southern American countries. With its presence in the Unites States, febit enters the largest market for biochip technology worldwide.
Thus, GENIOM sales and customer support will be handled by qualified stuff on site. All team members are experienced in the US market.
The knowledge transfer required for a start of febit Inc. was achieved by several months of prior training for technical specialists and the US management.
Temporary delegation of febit biotech gmbh staff is envisaged as well. A fully equipped application laboratory is already established that will enable customers to perform hands-on tests of their applications on the GENIOM system and develop assays in cooperation with febit Inc.
In addition, febit will offer workshops featuring various GENIOM applications. Production for the Americas (Northern and Southern America) is expected to take place in close cooperation with US-based companies.
febit Inc. is directed by Claus E. Schmidt, Vice President Operations & General Manager, an entrepreneur experienced in knowledge transfer between Europe and the USA.
In addition, he contributes expertise in the field of chemical engineering. febit Inc. CEO Cord F. Stahler directs febit biotech gmbh in Heidelberg as well and is an accomplished manager in the international biomedical technology business.
The Operative Management is completed by Stefan M. Matysiak, PhD, Director Customer Care, who is primarily responsible for customer care and the applications laboratory.
He has several years of experience in research and development, working for renowned companies and institutions in the US and Germany, such as Applied Biosystems Inc. and the German Cancer Research Center.
The Supervisory Board of febit Inc. - as the one of febit biotech gmbh - is chaired by Dr. Gerald Moller, Director of HBM BioCapital Management GmbH and former president and CEO of the Boehringer Mannheim Group.
Vice Chairman of the Supervisory Board is Michael Kranich, Director of DH-Capital GmbH & Co. KG and OH-Beteiligungen GmbH & Co. KG that holds the majority of febit biotech GmbH for the Hopp family.
Dietmar Hopp, co-founder of SAP and its CEO and Chairman for many years, is the most potent single investor of the German biotech industry.
He primarily invests in young, promising companies in that business such as febit biotech gmbh. Supporting febit´s establishment on the American continent, he expands his engagement in the fastest-growing biotech market.
Establishing a US-based company is a logical step for Cord F. Stahler, CEO of febit Inc, "After a successful start of GENIOM in the European market, penetration of the US as the largest biochip market is an essential move in our marketing strategy."
"We are confident that our US customers as well will be convinced by the unique speed and flexibility of our system in microarray synthesis and analysis."
"With a highly efficient team in the country, we are able to specifically address this market and successfully expand our business there."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018